Nutra Pharma Corp (NPHC) Liabilities and Shareholders Equity (2010 - 2026)

Nutra Pharma has disclosed Liabilities and Shareholders Equity across 17 years of filings, most recently posting $622863.0 for Q2 2026.

• In Q2 2026, Liabilities and Shareholders Equity fell 27.5% year-over-year to $622863.0; the TTM figure through Jun 2026 stood at $2.6 million (down 7.9% YoY), while the FY2025 annual figure was $622601.0, up 3.85% from the prior year.
• Liabilities and Shareholders Equity came in at $622863.0 for Q2 2026 at Nutra Pharma, up from $616518.0 in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $859068.0 in Q2 2025 to a low of $558838.0 in Q3 2024.
• Average Liabilities and Shareholders Equity over 5 years is $689950.6, with a median of $700255.5 recorded in 2022.
• Year-over-year, Liabilities and Shareholders Equity soared 78.39% in 2022 and declined 27.5% in 2026.
• Over 5 years, Liabilities and Shareholders Equity stood at $754913.0 in 2022, then dropped by 15.17% to $640397.0 in 2023, then dropped by 6.39% to $599495.0 in 2024, then gained by 3.85% to $622601.0 in 2025, then rose by 0.04% to $622863.0 in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $622863.0 in Q2 2026, $616518.0 in Q1 2026, and $622601.0 in Q4 2025.